IQVIA Holdings, Inc. Common Stock (IQV)

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.

Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.

Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.

Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.

IQVIA reports Q1 EPS of $2.70 and revenue of $3.83 billion, raises 2025 sales outlook and highlights strong growth in analytics and R&D pipeline metrics.

Clinical research company IQVIA (NYSE: IQV) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 2.5% year on year to $3.83 billion. The company’s full-year revenue guidance of $16.2 billion at the midpoint came in 2.1% above analysts’ estimates. Its non-GAAP profit of $2.70 per share was 2.6% above analysts’ consensus estimates.

Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting.

Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics.

Clinical research company IQVIA (NYSE: IQV) will be reporting earnings tomorrow before the bell. Here’s what to expect.

Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year?

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 10.9%. This drawdown was worse than the S&P 500’s 5.7% decline.

Curious about which S&P500 stocks are generating unusual volume on Wednesday? Find out below.

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest of the drug development inputs & services stocks fared in Q4.